Search
Citrus bioflavonoids
go.drugbank.com/drugs/DB14586ApprovedMixtures: Rose Hips 500plus Nu Life, Bioflavonoids With Rose Hips C Nu LifeSodium phosphate, dibasic
go.drugbank.com/drugs/DB14502ApprovedInvestigationalMixtures: Tis-U-Sol, Tis-U-solCamizestrant
go.drugbank.com/drugs/DB19218ApprovedInvestigational[L64094,L64107] The European Commission approved camizestrant on July 23, 2026, Health Canada authorized it on August 4, 2026, and the FDA granted accelerated approval on September 4, 2026. … [L64094,L64107] Patients are selected for treatment on the basis of an *ESR1* mutation detected by circulating tumor DNA testing during first-line endocrine therapy, before radiographic disease progression
Synonyms: 3-pyridinamine, n-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6s,8r)-6,7,8,9-tetrahydro-8-methyl-7-(2,2,2-trifluoroethyl)-3h-pyrazolo(4,3-f)isoquinolin-6-yl)-, N-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6s,8r)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3h-pyrazolo(4,3-f)isoquinolin-6-yl)-3-pyridinamineErgoloid mesylate
go.drugbank.com/drugs/DB01049Approved[A32914] The mixture of ergoloid mesylate was first developed by Novartis and FDA approved on November 5, 1953, but this specific formulation is now discontinued. … [T90] The derivatives of this fungus are identified to be about 350 different substances from which the components of the ergoloid mesylate mixture are composed of the dihydrogenated ergot alkaloid derivatives
Categories: Heterocyclic Compounds with 4 or More Rings, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeLacidipine
go.drugbank.com/drugs/DB09236ApprovedDue to its long duration of action, lacidipine does not lead to reflex tachycardia [A31536]. … It is available as once-daily oral tablets containing 2 or 4 mg of the active compound commonly marketed as Lacipil or Motens. It is not currently FDA-approved.
Sofosbuvir
go.drugbank.com/drugs/DB08934ApprovedInvestigationalEpclusa is also currently the most potent HCV antiviral medication on the market with a sustained virologic response (SVR) after 12 weeks of therapy of 93-99% depending on genotype and level of cirrhosis … Approved in October 2014 by the FDA, Harvoni is indicated for the treatment of HCV genotypes 1, 4, 5, and 6 with or without [DB00811] depending on the level of liver damage or cirrhosis [FDA Label].
Categories: Antivirals for treatment of HCV infectionsTetrachlorodecaoxide
go.drugbank.com/drugs/DB05389ApprovedThe Corporation believes the research to-date demonstrates that WF10 acts on macrophages (a type of white blood cell) by modulating the balance between inflammation and phagocytosis, a state in which the … The Corporation has commenced a Phase II clinical trial in an effort to demonstrate the efficacy of WF10 in combination with Xeloda (capecitabine) in the treatment of pancreatic cancer.
Categories: Compounds used in a research, industrial, or household settingDosulepin
go.drugbank.com/drugs/DB09167ApprovedInvestigationalIt is not FDA-approved due to low therpeutic index and significant toxicity in overdose. … The use of dosulepsin is only recommended in patients who are intolerant or unresponsive to alternative antidepressant therapies.
Synonyms: (3E)-3-dibenzo[b,e]thiepin-11(6H)-ylidene-N,N-dimethylpropan-1-amineCategories: Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeTechnetium Tc-99m etidronate
go.drugbank.com/drugs/DB09411ApprovedCategories: Diagnostic Uses of Chemicals, Compounds used in a research, industrial, or household settingDiethylstilbestrol
go.drugbank.com/drugs/DB00255ApprovedWithdrawnAccording to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. … (Merck, 11th ed) The FDA withdrew its approval for the use of all oral and parenteral drug products containing 25 milligrams or more of diethylstilbestrol per unit dose.[L43942]
Categories: Sex Hormones and Modulators of the Genital System, Estrogens, Non-Steroidal